BioSyent Inc. (TSXV:RX)

Market Cap	165.17M +43.0%
Revenue (ttm)	45.98M +20.1%
Net Income	9.04M +15.5%
EPS	0.78 +17.5%
Shares Out	11.44M
PE Ratio	18.42
Forward PE	15.53
Dividend	0.22 (1.52%)
Ex-Dividend Date	May 29, 2026

Volume	9,612
Average Volume	5,802
Open	14.55
Previous Close	14.43
Day's Range	14.41 - 14.55
52-Week Range	10.65 - 15.80
Beta	0.64
RSI	42.93
Earnings Date	May 14, 2026

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2025, BioSyent's revenue was 43.05 million, an increase of 22.90% compared to the previous year's 35.03 million. Earnings were 9.01 million, an increase of 23.96%.